Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NanoString debuts spatial molecular imaging platform

By Brian Buntz | December 2, 2020

NanoStringNanoString Technologies Inc. (NSDQ:NSTG) has announced a spatial molecular imaging platform for multiplexed analysis of RNA and protein expression for individual cells within intact tissue samples. 

The spatial molecular imaging (SMI) platform supports tissue samples of Formalin-fixed paraffin-embedded and fresh-frozen specimens as well as organoids. 

The SMI platform is designed to complement the company’s GeoMx digital spatial profiler, which supports the analysis of hundreds to thousands of RNAs or proteins from single cells within morphologically intact tissue samples. The profiler supports cellular and sub-cellular resolution. 

“Spatial imagers measuring RNA and protein in situ at single-cell and sub-cell resolution are expected to emerge as an important product category over the next several years,” said Brad Gray, NanoString president and CEO, in prepared remarks. 

The SMI will be formally available in the first half of 2021. 

NanoString’s GeoMx has been a moneymaker for the company, helping to accelerate revenue growth in 2020. According to a briefing note from the investment bank UBS, the 3D spatial tool addresses one of the most attractive end-market opportunities in diagnostic tools.


Filed Under: Drug Discovery and Development
Tagged With: GeoMx, NanoString Technologies, spatial molecular imaging, spatial molecular imaging platform
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
GSK
GSK to invest £1 billion on infectious disease research
CB Therapeutics
CB Therapeutics hires new business development lead

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50